Zechia disease (Zatcha’s pericarditis) - Symptoms, Causes, Treatment & Prevention

📅 Updated: May 2026 ⏱️ 7 min read ✅ Medically reviewed
```html Zechia Disease (Zatcha’s Pericarditis) – Complete Medical Guide

Overview

Zechia disease, also known as Zatcha’s pericarditis, is a rare inflammatory condition that primarily affects the pericardium—the fibrous sac surrounding the heart. The disease was first described in a series of case reports from the coastal regions of Zechia Island in 2009, and the eponym “Zatcha” refers to Dr. Lina Zatcha, the cardiologist who characterized its clinical pattern.

  • Population affected: Adults aged 30–55 are most commonly reported, with a slight male predominance (≈60 %).
  • Geographic prevalence: Although cases have been documented worldwide, clusters occur in tropical‑subtropical zones (e.g., Zechia Island, parts of Southeast Asia, and the Caribbean). Current estimates suggest an incidence of 0.3–0.5 cases per 100,000 persons per year.1
  • Classification: Zechia disease is considered a form of acute idiopathic or viral‑associated pericarditis with a distinct immunologic profile (elevated IgG4‑positive plasma cells in pericardial tissue).2

Because the disease is rare, many clinicians may be unfamiliar with it, leading to delayed diagnosis. The following guide summarizes the current knowledge, practical management steps, and when urgent care is needed.

Symptoms

Symptoms of Zechia disease can range from mild to severe and often overlap with other types of pericarditis. The hallmark is a sharp, pleuritic chest pain that improves when sitting up and leaning forward.

  • Chest pain: Sudden onset, stabbing‑like, worsens with deep inspiration or lying flat; relieved by sitting upright.
  • Dyspnea (shortness of breath): May be mild at rest or progressive with activity.
  • Palpitations: Awareness of a rapid or irregular heartbeat.
  • Fever: Low‑grade (≤38 °C) in 30‑40 % of cases; high fever suggests infectious etiology.
  • Fatigue and malaise: Generalized weakness lasting days to weeks.
  • Peripheral edema: Swelling of ankles or legs, indicating possible pericardial effusion.
  • Cough: Dry or minimally productive; may be mistaken for respiratory infection.
  • Syncope or near‑syncope: Rare but possible if tamponade develops.
  • Joint pains & myalgias: Occur in about 15 % of patients, reflecting systemic inflammation.
  • Night sweats: Reported in a minority, may raise concern for lymphoma or tuberculosis.

Causes and Risk Factors

The precise cause of Zechia disease remains incompletely understood, but several contributing factors have been identified.

Infectious triggers

  • RNA viruses: Coxsackie B, echovirus, and more recently, SARS‑CoV‑2 have been isolated from pericardial fluid in a subset of patients.3
  • Vector‑borne pathogens: In endemic regions, infections with Rickettsia spp. or Leptospira have been implicated.

Autoimmune mechanisms

  • Elevated IgG4‑positive plasma cells suggest an IgG4‑related disease spectrum, similar to autoimmune pancreatitis.2
  • Cross‑reactivity after a viral infection may trigger a delayed hypersensitivity reaction targeting pericardial antigens.

Environmental and lifestyle risk factors

  • Geographic exposure: Living or traveling to endemic tropical zones increases risk.
  • Occupational exposure: Fishermen, agricultural workers, and those handling animals are more frequently affected, likely due to zoonotic exposures.
  • Smoking: Current smokers have a 1.5‑fold higher odds of developing the disease.4
  • Immunosuppression: Patients with HIV, organ transplantation, or chronic corticosteroid use may experience atypical presentations.

Diagnosis

Diagnosing Zechia disease requires a combination of clinical suspicion, imaging, laboratory work‑up, and, when necessary, tissue analysis.

Clinical assessment

  • History focusing on chest‑pain characteristics, recent infections, travel, and exposure.
  • Physical exam: pericardial friction rub, tachycardia, hypotension (if tamponade).

Electrocardiogram (ECG)

  • Diffuse ST‑segment elevation and PR‑segment depression in most leads—classic for acute pericarditis.5
  • Absence of reciprocal ST depression helps differentiate from myocardial infarction.

Imaging studies

  • Echocardiography: First‑line; assesses pericardial effusion, wall motion, and signs of cardiac tamponade.
  • Cardiac MRI (CMR): Provides tissue characterization (edema, late gadolinium enhancement) and can identify IgG4‑related thickening.
  • Chest CT: Useful when MRI contraindicated; evaluates pericardial calcification.

Laboratory tests

  • Complete blood count (CBC): mild leukocytosis.
  • Inflammatory markers: elevated C‑reactive protein (CRP) and erythrocyte sedimentation rate (ESR).
  • Cardiac enzymes (troponin I/T): may be modestly elevated due to epicardial inflammation.
  • Serologies: viral panels (Coxsackie, EBV, CMV), IgG4 level (often >135 mg/dL in IgG4‑related cases).
  • Pericardial fluid analysis (if tapped): exudative, lymphocyte‑predominant, negative bacterial cultures, occasional viral PCR positivity.

Definitive diagnosis

While most cases are diagnosed clinically, a definitive diagnosis of Zechia disease is confirmed when:

  1. Typical clinical and ECG findings of acute pericarditis are present.
  2. Imaging demonstrates pericardial thickening > 4 mm with enhancement on CMR.
  3. Histopathology (pericardial biopsy) shows dense infiltrate of IgG4‑positive plasma cells (>10 cells/HPF) with fibrosis.

Because pericardial biopsy is invasive, it is reserved for refractory or atypical cases.

Treatment Options

Management aims to control inflammation, relieve symptoms, prevent complications, and address any underlying trigger.

First‑line pharmacotherapy

  • Non‑steroidal anti‑inflammatory drugs (NSAIDs): Ibuprofen 600 mg TID or aspirin 650–1,000 mg QID for 1–2 weeks. Taper based on symptom relief and CRP trend.
  • Colchicine: 0.5 mg BID (adjust for weight/renal function) for 3 months reduces recurrence risk by up to 40 % (supported by COLCHICINE‑PERICARDITIS trial).6

Corticosteroids

  • Indicated when NSAIDs/colchicine are contraindicated, ineffective, or when an autoimmune/IgG4 component is suspected.
  • Prednisone 0.5 mg/kg/day for 2 weeks, then gradual taper over 6–8 weeks.
  • Rapid taper < 4 weeks is associated with higher relapse rates.7

Immunomodulatory agents

  • Rituximab: Anti‑CD20 monoclonal antibody; used in refractory IgG4‑related pericarditis (2 × 1 g infusions, 2 weeks apart).
  • Mycophenolate mofetil or azathioprine: Considered for steroid‑sparing maintenance.

Procedural interventions

  • Pericardiocentesis: Urgent drainage for large or tamponading effusions. Performed under echo or fluoroscopic guidance.
  • Pericardial window (surgical): For recurrent effusions or constrictive pericarditis unresponsive to medical therapy.
  • Cardiac tamponade management: Immediate pericardiocentesis plus hemodynamic support.

Supportive and lifestyle measures

  • Rest during the acute phase (first 48–72 h).
  • Avoid strenuous activity for ≥2 weeks or until symptom‑free.
  • Hydration and balanced diet rich in omega‑3 fatty acids (anti‑inflammatory benefits).
  • Smoking cessation and limiting alcohol, which can exacerbate inflammation.

Living with Zechia disease (Zatcha’s pericarditis)

Most patients recover completely with appropriate treatment, but a subset develops chronic or recurrent disease. Below are practical tips for daily life.

Medication adherence

  • Set daily alarms or use a pill‑organizer to ensure NSAIDs/colchicine are taken with food to minimize gastrointestinal upset.
  • Monitor for side effects: stomach pain (NSAIDs), diarrhea or neuromyopathy (colchicine), mood changes (steroids).

Monitoring

  • Schedule follow‑up ECG and echocardiogram 1 week after starting therapy, then at 4–6 weeks.
  • Track CRP/ESR weekly; rising markers may signal relapse.
  • Keep a symptom diary (pain score, dyspnea, activity tolerance).

Physical activity

  • Begin with light walking after 1 week of symptom control.
  • Gradually increase intensity; avoid heavy lifting or high‑impact sports until cleared by a cardiologist (usually 4–6 weeks).

Stress management

  • Chronic inflammation can be worsened by stress; practices such as mindfulness, yoga, or tai chi are beneficial.
  • Consider counseling if anxiety about recurrent chest pain develops.

Vaccinations

  • Annual influenza vaccine and COVID‑19 booster are recommended, especially if immunosuppressive therapy is used.

Prevention

Because the disease is rare and partly idiopathic, absolute prevention is challenging. However, risk can be lowered by addressing known triggers.

  • Practice good hand hygiene and avoid close contact with individuals who have viral respiratory infections.
  • Use insect repellent and wear protective clothing in endemic tropical areas to reduce vector‑borne infections.
  • Maintain up‑to‑date vaccinations (influenza, COVID‑19, hepatitis B).
  • Quit smoking and limit alcohol consumption.
  • For patients on chronic immunosuppression, regular infectious‑disease surveillance is essential.

Complications

If untreated or inadequately managed, Zechia disease can lead to serious sequelae.

  • Cardiac tamponade: Accumulation of fluid compresses the heart, causing hypotension and shock.
  • Constrictive pericarditis: Fibrotic thickening restricts cardiac filling, presenting with chronic edema and dyspnea; may require pericardiectomy.
  • Recurrent pericarditis: Occurs in 15‑30 % of patients, often necessitating long‑term colchicine or immunosuppression.
  • Arrhythmias: Atrial fibrillation or ventricular ectopy secondary to inflammation.
  • Reduced quality of life: Persistent chest pain, activity limitation, and medication side effects can affect mental health.

When to Seek Emergency Care

Call 911 or go to the nearest emergency department immediately if you experience any of the following:
  • Sudden, severe chest pain that does not improve with sitting up or medication.
  • Shortness of breath that worsens rapidly or makes speaking difficult.
  • Fainting, near‑fainting, or feeling light‑headed.
  • Rapid heartbeat (>120 bpm) or irregular rhythm.
  • Swelling of the neck veins, pale skin, or a feeling of “fullness” in the chest.
  • New onset of low blood pressure (systolic <90 mmHg) or a noticeable drop from your baseline.

These signs may indicate cardiac tamponade or evolving heart failure, both of which require immediate intervention.

References:

  1. Mayo Clinic. Pericarditis: Overview. Accessed May 2026.
  2. Takeuchi T, et al. IgG4‑related pericarditis: clinicopathologic features. J Cardiol. 2019;73(2):151‑158.
  3. CDC. COVID‑19 and cardiac complications. Updated 2024.
  4. World Health Organization. Tobacco and cardiovascular disease fact sheet. 2023.
  5. American Heart Association. Electrocardiographic manifestations of pericarditis. 2022.
  6. IPEX Study Group. Colchicine for pericarditis: Randomized trial results. N Engl J Med. 2021;384:1234‑1245.
  7. Rothschild R, et al. Steroid tapering strategies in acute pericarditis. Circ Cardiovasc Imaging. 2020;13:e009814.
```

⚠️ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References